Cepheid and other diagnostics players presented updates on rapid multiplex infectious disease testing at ESCMID, including workflow improvements designed to improve diagnostic stewardship. Coverage highlighted real-world data on fast panels and the expansion of syndromic testing capabilities, with Cepheid describing its first highly multiplexed product as a step into a crowded GI/ID testing space. The presentations also emphasized practical implementation details such as pretest probability selection, which can depend on season, region, and patient factors. In a respiratory sample study of 1,924 emergency department cases, a research-use respiratory test detected far more positives than standard reference workflows, illustrating the operational implications of rapid multiplex adoption. As IVDR implementation tightens the regulatory environment for diagnostics across Europe, these kinds of rapid, multiplex systems may face both increased compliance scrutiny and heightened demand to reduce time-to-targeted therapy.